Engineering the protein targeting two pathways of cerebral ischemia reperfusion injury provides better neuroprotective effect than targeting one pathway

Yu Kuai,Li Ruyi,Zhu Yuanjun,Liu Xiaoyan,Wang Yinye

DOI: https://doi.org/10.5246/jcps.2019.11.072

2019-01-01

Journal of Chinese Pharmaceutical Sciences

Abstract:We hypothesized that neuroprotective agents targeting various pathways involved in cerebral ischemia/reperfusion (I/R)injury might be superior to that targeting single pathway.Here,we prepared a fusion protein (B-I) by combining anti-apoptotic Bcl-xL (B) and anti-inflammatory IL-10 (I).B-I could cross blood brain barrier by its N-terminal TAT domain,and be cleaved into separate B and I by Caspase-1.B-I treatment significantly reduced the cerebral infarct volume,better than B or I treatment alone,and equivalent to B and I treatment (B+I).Treatment with B or B-I significantly attenuated I/R-induced neuronal apoptosis as shown by the decrease in apoptotic rate and the inhibition ofcaspase-3 activity.Moreover,all recombinant proteins,especially B-I,remarkably attenuated I/R-induced up-regulation of TNF-α.These results suggested that fusion protein B-I inhibiting both inflammation and apoptosis provided better neuroprotective effects than inhibiting either one alone.Our study suggested that multiple pathways targeting brain I-R injury could enhance the neuroprotective effect,and it provided a new idea for the study of neuroprotective drugs for ischemic stroke.